Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial

Andreas Maieron, Sigrid Metz-Gercek, Thomas-Matthias Scherzer, Hermann Laferl, Gabriele Fischer, Martin Bischof, Michael Gschwantler, Peter Ferenci, Andreas Maieron, Sigrid Metz-Gercek, Thomas-Matthias Scherzer, Hermann Laferl, Gabriele Fischer, Martin Bischof, Michael Gschwantler, Peter Ferenci

Abstract

Background: Chronic hepatitis C (CHC) Patients, infected with genotype (GT) 2 or 3 are treated with Peg-IFN and ribavirin (RBV) (800 mg/day) for 24 weeks. Treatment duration can be shortened to 12-16 weeks if a higher dose of RBV (1.000/1.200 mg/day) was used without considerable loss of responsiveness or increased risk of relapse. Previously we have shown that in patients with CHC, GT 2/3 RBV can be reduced to 400 mg/day if administered for 24 weeks without an increase in relapse rates. Therefore we investigated the efficacy of a reduced RBV dosage of 400 mg/day with shorter treatment duration (16 weeks).

Methods: Treatment naïve patients with CHC, GT 2/3 were randomized to receive 180 μg peginterferonα2a/week in combination with either 800 (group C) or 400 mg/d (group D) for 16 weeks. The primary endpoint was SVR.

Results: 12 months after the first patient was randomized a inferior outcome of group D as compared to group C was noted, therefore the study was terminated. At study termination 89 patients were enrolled (group C: 31, D: 51). The SVR rate was statistically different in the two study groups with 51.6% in group C and 28.4% in group D (p = 0.038). Patients with low viral load had higher SVR rates (C: 67%, D: 33%) than those with high viral load (C: 33%, D: 21%).

Conclusion: Both treatment duration and the dose of RBV play a major role to optimize outcome of patients with GT3. If one intends to shorten the treatment weight based RBV dose should be used, if lower RBV doses are used patients should be treated for at least 24 weeks as. A treatment regimen with a reduced RBV dosage and shortened treatment duration is associated with low SVR rates due to high relapse rates.

Trial registration: NCT01258101.

Figures

Figure 1
Figure 1
Patient flow.
Figure 2
Figure 2
Mean haemoglobin concentration during treatment and follow up.

References

    1. Alter HJ. HCV natural history: the retrospective and prospective in perspective. J Hepatol. 2005;43(4):550–552. doi: 10.1016/j.jhep.2005.07.002.
    1. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology. 2006;130(1):225–230. doi: 10.1053/j.gastro.2005.11.011.
    1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–982. doi: 10.1056/NEJMoa020047.
    1. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–355.
    1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–965. doi: 10.1016/S0140-6736(01)06102-5.
    1. Gaeta GB, Precone DF, Felaco FM, Bruno R, Spadaro A, Stornaiuolo G, Stanzione M, Ascione T, De Sena R, Campanone A, Filice G, Piccinino F. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther. 2002;16(9):1633–1639. doi: 10.1046/j.1365-2036.2002.01331.x.
    1. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352(25):2609–2617. doi: 10.1056/NEJMoa042608.
    1. Weiland O, Hollander A, Mattsson L, Glaumann H, Lindahl K, Schvarcz R, Lindh G, Enquist R, Quist A. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat. 2008;15(9):641–645. doi: 10.1111/j.1365-2893.2008.00999.x.
    1. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004;40(6):1260–1265. doi: 10.1002/hep.20467.
    1. Zeuzem S, Rizzetto M, Ferenci P, Shiffman ML. Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response. Antivir Ther. 2009;14(2):143–154.
    1. Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Loschenberger K. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology. 2008;47(6):1816–1823. doi: 10.1002/hep.22262.
    1. Han B, Enas NH, McEntegart D. Randomization by minimization for unbalanced treatment allocation. Stat Med. 2009;28(27):3329–3346. doi: 10.1002/sim.3710.
    1. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357(2):124–134. doi: 10.1056/NEJMoa066403.
    1. Berg T, Carosi G. Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3. Antivir Ther. 2008;13(Suppl 1):17–22.
    1. Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, Scotto G, Vinelli F, Ricci GL, Romano M, Carretta V, Petruzzellis D, Andriulli A. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology. 2009;49(2):358–363. doi: 10.1002/hep.22679.
    1. Di Martino V, Richou C, Thévenot T, Sánchez-Tapias S, Ferenci P. Modulations of PEG-Interferon plus Ribavirin duration according to HCV-genotype and virologic response at W4 and W12: Metaanalyses of RCTs with individual data. Hepatology. 2008;48:404A.
    1. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology. pp. 32–41.
    1. Scherzer TM, Hofer H, Staettermayer AF, Rutter K, Beinhardt S, Steindl-Munda P, Kerschner H, Kessler HH, Ferenci P. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol.
    1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. doi: 10.1038/nature08309.
    1. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–1104. doi: 10.1038/ng.447.
    1. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–1109. doi: 10.1038/ng.449.
    1. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. pp. 821–827. 827 e821.
    1. Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. pp. 1181–1189.
    1. Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology. pp. 389–395.
    1. Melin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Lang JP, Marcellin P, Cacoub P. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol. pp. 1050–1057.
    1. Semba RD, Ricketts EP, Mehta SF, Kirk GD, Latkin C, Galai N, Vlahov D. Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore. Am J Drug Alcohol Abuse. 2007;33(1):71–80. doi: 10.1080/00952990601082696.
    1. Grebely J, Matthews GV, Hellard M, Shaw D, van Beek I, Petoumenos K, Alavi M, Yeung B, Haber PS, Lloyd AR, Kaldor JM, Dore GJ. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol.
    1. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. pp. 123–135. e121-122.
    1. Schulte B, Schutt S, Brack J, Isernhagen K, Deibler P, Dilg C, Verthein U, Haasen C, Reimer J. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend.
    1. Ebner N, Wanner C, Winklbaur B, Matzenauer C, Jachmann CA, Thau K, Fischer G. Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Addict Biol. 2009;14(2):227–237. doi: 10.1111/j.1369-1600.2009.00148.x.
    1. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007;19(9):741–747. doi: 10.1097/MEG.0b013e3281bcb8d8.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir